Vitestro Unveils Aletta™: The World's First Autonomous Robotic Phlebotomy Device™ (ARPD™)

"The name Aletta fosters a human connection with both healthcare professionals and patients—making Aletta more than just technology," says Brian Joseph, Co-Founder and Commercial Director at Vitestro. Patients and healthcare staff will interact with Aletta every day, and we want them to see her as an integral part of the phlebotomy team. By working alongside trained medical personnel, Aletta enhances precision and efficiency, ensuring a seamless experience and the highest quality of care for every patient."
Comunicato Precedente

next
Comunicato Successivo

next
UTRECHT, The Netherlands, (informazione.it - comunicati stampa - salute e benessere)

"The name Aletta fosters a human connection with both healthcare professionals and patients—making Aletta more than just technology," says Brian Joseph, Co-Founder and Commercial Director at Vitestro. Patients and healthcare staff will interact with Aletta every day, and we want them to see her as an integral part of the phlebotomy team. By working alongside trained medical personnel, Aletta enhances precision and efficiency, ensuring a seamless experience and the highest quality of care for every patient."

Aletta is the first and only Autonomous Robotic Phlebotomy Device™ (ARPD™), a unique technology descriptor that establishes a new category of medical robotics dedicated to optimizing blood collection. As the exclusive ARPD™, Aletta sets the global industry standard for automated venous blood draws—enhancing clinical precision, safety, efficiency, and patient experience. By automating routine blood draws, Aletta enables phlebotomists and nurses to dedicate more time to patient care while addressing critical healthcare staffing shortages, which are expected to worsen in the coming years.

Aletta's advanced capabilities include:

Following its CE-marking and initial commercial launch in Europe, Vitestro is preparing for broader adoption of Aletta across hospitals and laboratories throughout the region. The company is also working towards U.S. regulatory approval and conducting a U.S.-based multi-center clinical trial in collaboration with leading academic medical centers and healthcare systems. As demand for autonomous blood collection increases, Vitestro aims to establish ARPD technology as the new global standard of care—expanding access to high-quality diagnostics while improving the patient experience.

"With Aletta, Vitestro is shaping the future of blood collection—where human expertise and robotic precision work together to advance healthcare while preserving the human touch."

Vitestro Unveils Aletta™: The World's First Autonomous Robotic Phlebotomy Device™ (ARPD™)

About Vitestro

Vitestro is a global leader in medical robotics, headquartered in the Netherlands, with deep expertise in engineering, robotics, and commercialization in both the U.S. and international markets. The company has developed and launched the world's first and only CE-marked Autonomous Robotic Phlebotomy Device™ (ARPD™), setting a new benchmark for diagnostic venous blood sampling. By integrating advanced robotics, artificial intelligence, and imaging technology, Vitestro delivers greater precision, efficiency, and an improved patient experience. While Aletta has not yet received FDA approval, Vitestro is actively preparing for U.S. regulatory approval and global expansion.

For more information, visit vitestro.com.

Cision View original content:https://www.prnewswire.co.uk/news-releases/vitestro-unveils-aletta-the-worlds-first-autonomous-robotic-phlebotomy-device-arpd-302394497.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili